• Explore /
  • Poster
  • / CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.

CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.

Abstract Poster

Authors

Ronan Kelly

Ronan Joseph Kelly

Johns Hopkins School of Medicine, Baltimore, MD

Ronan Joseph Kelly , Albert C. Lockhart , Derek J. Jonker , Bohuslav Melichar , Thierry Andre , Ian Chau , Stephen John Clarke , James M. Cleary , Yuichiro Doki , Fabio A. Franke , Yuko Kitagawa , Christophe Mariette , Paola Catherine Montenegro , Guillermo Ariel Mendez , Marika Ciprotti , Markus H. Moehler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02743494

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4131)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4131

Abstract #

TPS4131

Poster Bd #

123a

Abstract Disclosures

Similar Posters

First Author: Ronan Joseph Kelly

First Author: Luhua Wang

First Author: Anne-Claire Hardy-Bessard

First Author: Sherene Loi